Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over 18 years~* CML Philadelphia chromosome in chronic phase treated with nilotinib or ponatinib for, in first or second line~* Written informed consent must be obtained prior to protocol-specific procedures~* Affiliation to a social security category~Exclusion Criteria:~* Revascularization already decided and scheduled~* Life threatening disease~* Recent history of myocardial infarction or stroke~* Unstable angina~* Hypotension (Blood pressure \< 90/50mmHg)~* Pregnancy and lactation~* Women of childbearing potential not using appropriate contraceptive measures~* Contraindication for statin~* Contraindication for aspirin~* Contraindication for ACEi or AT2 antagonists treatment~* Known hypersensitivity to rosuvastatin or fluvastatin, other ingredients in the product~* Known hypersensitivity to aspirin, other ingredients in the product, other salicylates or non-steroidal anti-inflammatory drugs~* Known hypersensitivity to ACEi or AT2 antagonists treatment, other ingredients in the product~* Hereditary or idiopathic angioedema ; or history of angioedema~* Hyperaldosteronism~* Active liver disease, or unexplained, persistent elevations in serum transaminases~* Severe renal impairment (creatinine clearance \<30 ml/min)~* Myopathy~* Concomitant cyclosporine treatment~* History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy~* Severe heart failure~* Concurrent severe diseases which exclude the administration of therapy~* Patients under reinforced protection, deprived of liberty by judicial or administrative decision, hospitalized without consent or admitted to a health or social establishment for purposes other than research~* Absence of affiliation to a social security agency~* Inability to understand the instructions or objectives of the study~* Absence of signed informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active prevention (Type: EXPERIMENTAL): optimal medical treatment
- usual clinical practice (Type: SHAM_COMPARATOR): usual clinical practice in each center

Based on this trial design, predict the completion outcome and termination type (if applicable).